Abstract
A significant benefit of intraperitoneal regional chemotherapy (IPRC) has been demonstrated for the treatment and prevention of peritoneal carcinomatosis (PC) in stomach cancer [1,2] and malignant ascites [3] (see Chapter 7). IPRC also seems to be effective in peritoneal disease of various other tumor histologies and as second-line treatment in ovarian carcinoma [4–7]. The principle of IPRC aims at reaching high intraperitoneal drug concentrations at low systemic (intravenous) levels [5,8]. The advantage of intraperitoneal versus intravenous drug levels during IPRC varies from 18 to 620 [5], so that many drugs are qualified for IPRC from a pharmacokinetic point of view.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hagiwara A, Takahashi T, Kojima O, Sawai K, Yamaguchi T, Yamane T, Taniguchi H, Kitamura K, Noguchi A, Seiki K, Sakakura C. Prophylaxis wity carbon-absorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992;339:629–631.
Fujimoto S, Shrestha RD, Kokubun M, Kobayashi K, Kiuchi S, Konno C, Ohta M, Takahashi M, Kitsukawa Y, Mizutani M, Chikenji T, Okui K. Positive results of combined therapy of surgery and intraperitoneal hyerthermic perfusion for far-advanced gastric cancer. Ann Surg 1990;212:592–596.
Kaufmann M, Schmid H, Kubli F. Intraperitoneal Mitoxantron-Applikation beim progredienten Ovarialkarzinom mit Aszitesbildung. In Seeber S, Aigner KR, Enghofer E, eds. Onkologisches Kolloquium 2. Berlin: Walter de Gruyter, 1988, pp 61–70.
Markman M. Intracavitary chemotherapy. Crit Rev Oncol Hematal 1985;3:205–233.
Markman M. Intraperitoneal therapy in ovarian cancer utilizing agents achieving high local but low systemic exposures. Reg Cancer Treat 1991;3:264–268.
Brenner DE. Intraperitoneal chemotherapy: A review. J Clin Oncol 1986;4:1135–1147.
Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Lewis JL. Intraperitoneal versus intravenous cisplatin-based therapy in small-volume residual refractory ovarian cancer: Evidence supporting an advantage for local drug delivery. Reg Cancer Treat 1990;3:10–12.
Dedrick RL, Myers CE, Bunagy PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62: 1–11.
Link KH, Gisa C, Muhrer KH, Fischer HP, Altmannsberger M, Koehler A. Immunereactivity of colorectal carcinoma cell line NMG 64/84 in the electropheresis mobility test (EMT) (abstract). J Cancer Res Clin Oncol 1987;113:S43.
Link KH, Staib L, Beger HG. Influence of exposure concentration and exposure time cxt on toxicity of cytostatic drugs to HT29 human colorectal carcinoma cells. Reg Cancer Treat 1989;2:189–197.
Link KH, Aigner KR, Kessler D. In vitro chemosensitivity profiles of human malignancies for high-dose (regional) chemotherapy. Contrib Oncol 1988;29:28–42.
Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112–1118.
Richard JM, Kramar A, Molinari R, Lefebvre JL, Blanchet F, Jortay A, Sancho-Garnier H. Randomised EORTC head and neck cooperative group trial of preoperative intraarterial chemotherapy in oral cavity and oropharynx carcinoma. Eur J Cancer 1991;27:821–827.
Schroy PC III, Cohen A, Winawer SJ, Friedman EA. Effects of FUdR on primary-cultured colon carcinomas metastatic to the liver. J Surg Oncol 1990;45:217–223.
Hill BT. Use of continuous human tumour cell lines to evaluate drugs by clonogenic assay. In Dendy PP, Hill BT, eds. Human Tumour Drug Sensitivity Testing in Vitro. London: Academic Press, 1983, pp 129–146.
Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7: 425–432.
Link KH, Aigner KR, Kuehn W, Schwemmle K, Kern DH. Prospective correlative chemo-sensitivity testing in high-dose intraarterial chemotherapy for liver metastases. Cancer Res 1986;46:4837–4848.
Link KH, Aigner KR, Pillasch J, Ullrich J, Gansauge F, Kern DH. Individual chemosen-sitivity testing for regional chemotherapy in a prospective correlative and a prospective decision aiding test. Reg Cancer Treat 1993;3:113–120.
Alberts DS, Young L, Mason N, Salmon SE. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 1985;12:38–42.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers, Boston
About this chapter
Cite this chapter
Link, K.H., Butzer, U., Pillasch, J., Hepp, G., Beger, H.G. (1996). In vitro pharmalogic rationale for intraperitoneal regional chemotherapy. In: Sugarbaker, P.H. (eds) Peritoneal Carcinomatosis: Principles of Management. Cancer Treatment and Research, vol 82. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1247-5_7
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1247-5_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8531-1
Online ISBN: 978-1-4613-1247-5
eBook Packages: Springer Book Archive